Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2020
A new biosimilar to NovoRapid is included in the high-cost protection
28 August 2020 - Insulin aspart Sanofi (insulin aspart) solution for injection for the treatment of diabetes is included in ...
Posted by Michael Wonder on 29 Aug 2020
Rybelsus is included in the high-cost protection with restriction
28 August 2020 - Rybelsus (semaglutide) is intended for the treatment of adults with type 2 diabetes in adults as the ...
Posted by Michael Wonder on 08 Jul 2020
TLV is reviewing the subsidy of SGLT-2 inhibitors
8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors. ...
Posted by Michael Wonder on 30 Jun 2020
FINOSE - Nordic cooperation extended to promote patients' access to medicines
30 June 2020 - The latest FINOSE report is used as the basis of all the five Nordic countries in ...
Posted by Michael Wonder on 29 Jun 2020
Health economic assessment of Ondexxya in life-threatening or uncontrolled bleeding
26 June 2020 - TLV has developed a health economic assessment for the regions of the drug Ondexxya (andexanet alfa). ...
Posted by Michael Wonder on 28 Jun 2020
The reimbursement for medicines is expected to decrease by SEK 185 million in 2020
26 June 2020 - Pharmaceutical companies will pay SEK 2.9 billion in reimbursement for medicines covered by side agreements between ...
Posted by Michael Wonder on 18 Jun 2020
TLV has decided to change the subsidy status for certain drugs
18 June 2020 - TLV has reviewed the subsidy status for drugs that are included in the Swedish Medicines Agency's ...
Posted by Michael Wonder on 11 Jun 2020
Health economic assessment of Waylivra in familial chylomicronaemia
11 June 2020 - TLV has made a health economic assessment to the regions of the drug Waylivra (volansorsen). ...
Posted by Michael Wonder on 09 Jun 2020
Desloratadine new exchange groups
9 June 2020 - As of 1 July, desloratadine will be included as exchange group on the list of products ...
Posted by Michael Wonder on 08 Jun 2020
Health economic assessment of Polivy in combination with bendamustine and rituximab
5 June 2020 - The treatment is intended for adult patients with diffuse large-cell B-cell lymphomas who relapse or do not ...
Posted by Michael Wonder on 02 Jun 2020
More patients have access to medicines within the high-cost protection system
2 June 2020 - From today, patients who pick up prescription drugs at pharmacies will be able to switch to ...
Posted by Michael Wonder on 01 Jun 2020
Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)
29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) ...
Posted by Michael Wonder on 28 May 2020
TLV has decided to reconsider the subsidy status for certain drugs
26 May 2020 - TLV initiates a review for review of subsidy status for drugs that are part of one ...
Posted by Michael Wonder on 18 May 2020
Health economic assessment of Bavencio and Inlyta
18 May 2020 - TLV has developed a health economic assessment for the regions regarding the combination of avelumab (Bavencio) and ...
Posted by Michael Wonder on 14 May 2020
Camurus' Buvidal reimbursed in Sweden for the treatment of opioid dependence
14 May 2020 - Buvidal (buprenorphine) prolonged release injection receives reimbursement in Sweden from the 15 May 2020 after approval by ...